Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Comprehensive screening for PD-L1 expression in thyroid cancer

Open access
Ahn, Soomin, Kim, Tae Hyuk, Kim, Sun Wook, Ki, Chang Seok, Jang, Hye Won, Kim, Jee Soo, Kim, Jung Han, Choe, Jun-Ho, Shin, Jung Hee, Hahn, Soo Yeon, Oh, Young Lyun, Chung, Jae Hoon · 2017 · Endocrine-Related Cancer

Abstract

PD-L1 expression is being considered a potential biomarker for response of anti-PD-1 or anti-PD-L1 agents in various tumors. The reported frequency of PD-L1 positivity varies in thyroid carcinomas, and multiple factors may contribute to the variability in PD-L1 positivity. We evaluated the PD-L1 expression in various thyroid cancers on a large scale. A total of 407 primary thyroid cancers with a median 13.7-year of follow-up were included. We evaluated the frequency of PD-L1 expression using a rabbit monoclonal antibody (clone SP142). In addition, we analyzed the relationships between PD-L1 expression and clinicopathologic factors, including TERT promoter , BRAF status and disease progression. Tumoral PD-L1 was expressed in 6.1% of papillary thyroid carcinomas, 7.6% of follicular thyroid carcinomas and 22.2% of anaplastic thyroid carcinomas. The distribution of PD-L1 positivity was different according to cancer histology types ( P < 0.001). All PD-L1-positive cases of follicular thyroid carcinoma and anaplastic thyroid carcinoma showed strong intensity. The proportions of positivity in PD-L1 positive anaplastic thyroid carcinomas were more than 80%. PD-L1 in immune cells was positive in 28.5% of papillary thyroid carcinoma, 9.1% of follicular thyroid carcinomas and 11.1% of anaplastic thyroid carcinomas. There was no significant association between clinicopathologic variables, disease progression, oncogenic mutation and PD-L1 expression. PD-L1 was highly expressed in a subset of patients with advanced thyroid cancer, such as follicular and anaplastic thyroid carcinoma. Identification of PD-L1 expression may have direct therapeutic relevance to patients with refractory thyroid cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/erc-16-0421

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 173

Metadata

Authors
Ahn, S., Kim, T. H., Kim, S. W., Ki, C. S., Jang, H. W., Kim, J. S., Kim, J. H., Choe, J.-H., Shin, J. H., Hahn, S. Y., Oh, Y. L., & Chung, J. H.
Venue
Endocrine-Related Cancer
Published
2017-02
Volume
24
Issue
2
Pages
97-106
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2572623634
Cited by
173
References
7
FWCI
9.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive screening for PD-L1 expression in thyroid cancer. https://app.cochat.ai/papers/10.1530/erc-16-0421
The paper
Ahn, S., Kim, T. H., Kim, S. W., Ki, C. S., Jang, H. W., Kim, J. S., Kim, J. H., Choe, J.-H., Shin, J. H., Hahn, S. Y., Oh, Y. L., & Chung, J. H. (2017). Comprehensive screening for PD-L1 expression in thyroid cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-16-0421

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.